CLN5 (Ceroid Lipofuscinosis, Neuronal 5) is a soluble lysosomal protein belonging to the ceroid lipofuscinosis family. Mutations in CLN5 cause variant late infantile neuronal ceroid lipofuscinosis (vLINCL), also known as Finnish variant LINCL, a fatal neurodegenerative lysosomal storage disorder characterized by progressive loss of vision, motor function, and cognition [1].
CLN5 (Ceroid Lipofuscinosis, Neuronal 5) is a soluble lysosomal protein belonging to the ceroid lipofuscinosis family. Mutations in CLN5 cause variant late infantile neuronal ceroid lipofuscinosis (vLINCL), also known as Finnish variant LINCL, a fatal neurodegenerative lysosomal storage disorder characterized by progressive loss of vision, motor function, and cognition [1].
CLN5 encodes a soluble lysosomal protein mutated in variant late infantile neuronal ceroid lipofuscinosis (vLINCL). The disease typically presents between ages 4-7 with seizures and visual loss. CLN5 is a glycoprotein with a β-propeller fold that participates in lysosomal function and [autophagy](/entities/autophagy).
β-propeller fold: Characteristic structure suggesting a role in protein-protein interactions
Signal peptide: N-terminal signal sequence for lysosomal targeting
Post-translational modification: Processed in the Golgi to mature form
Molecular Function
Lysosomal Enzyme Activity
CLN5 functions as a soluble lysosomal protein that may act as a co-factor for other lysosomal enzymes. Studies suggest it interacts with CLN3 and other CLN proteins to maintain lysosomal homeostasis [2].
Autophagy Regulation
CLN5 plays a role in regulating the autophagy-lysosomal pathway. Loss of function leads to impaired autophagic flux and accumulation of autofluorescent lipopigments in [neurons](/entities/neurons).
Protein-Protein Interactions
CLN3: Interacts with CLN5 in lysosomal membrane complexes
CLN8: May function in ER-lysosome trafficking
PPT1: Palmitoyl protein thioesterase 1 - related CLN disease protein
Role in Disease
Variant Late Infantile Neuronal Ceroid Lipofuscinosis (vLINCL)
The study of Cln5 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[1] [Mole SE, et al. CLN5 disease: genetics and pathogenesis. Biochim Biophys Acta. 2020](https://pubmed.ncbi.nlm.nih.gov/32861678/)
[2] [Lebrun AH, et al. CLN5 mutations cause vLINCL. J Med Genet. 2009](https://pubmed.ncbi.nlm.nih.gov/19491314/)